Novel Treatment Advances and Approaches in the Management of Relapsed/Refractory Multiple Myeloma: Expert Strategies on the Role of Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from June 1, 2020 to June 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme

Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. There are several novel options that have recently been approved for relapsed or refractory multiple myeloma that have shown great promise in their ability to improve clinical outcomes. Multiple Myeloma is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as the hemoglobin and serum calcium concentrations, the number of lytic bone lesions, and the presence or absence of renal failure. The stage of the disease at presentation is a strong determinant of survival. Treatment selection is influenced by the age and general health of the patient, prior therapy, and the presence of complications of the disease. Despite treatment advances in the last several years, multiple myeloma remains a disease with poor long-term survival as it is currently incurable and all patients will eventually relapse, underlining the need for new therapies. Fortunately for patients with MM, new options have been approved for heavily pretreated disease, including selective inhibitor of nuclear export compounds, most of which appear to improve patient outcomes at a significant rate.

Upon completion of this activity, participants will be able to:

  • Compare and contrast efficacy and safety profiles of novel agent classes and next-generation therapeutics for patients with relapsed/refractory multiple myeloma

  • Analyze the role of emerging anti-CD38 monoclonal antibodies in the relapsed/refractory multiple myeloma treatment paradigm

  • Examine best practices with respect to communication and coordination among members of the multidisciplinary myeloma care team

  • Explore managed care considerations of emerging therapies by exploring where these potential agents may fit into current relapsed/refractory multiple myeloma management paradigm

  • Evaluate strategies for managing treatment-related adverse events in patients with relapsed/refractory multiple myeloma who are receiving therapy with regimens that contain novel components

  • Assess the clinical utility of MRD assessment in relapsed/refractory multiple myeloma, and how it can be applied to inform treatment decisions with emerging therapies

Faculty: Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute


Dr. Lonial serves as a consultant to Amgen, BMS, Celgene, GSK, Janssen, Merck, Novartis, and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue